



Patient Name: UniPath, Sample Heme

Birth Date: 1/1/1901 Age: 103

Sex: Male

Accession Number: FC88-000201

Morphologic Accession No:

Date Obtained: 1/14/2004

Date Received: 1/14/2004

Clinician: UniPath Referring Physician * 123 Main St * Denver, CO 80022 303-512-0888

Specimen Information:

Pertinent History: Left and right cervical adenopathy; Medical Record Number: MRN1234

Interpretation:

PERIPHERAL T-CELL LYMPHOMA, SEE COMMENT.





Comment:

There is a 35-40% population of highly aberrant mature T lymphocytes in this specimen. There is partial CD10 expression by these cells, which has been associated with angioimmunoblastic T-cell lymphoma. Molecular studies to confirm T-cell clonality are pending. Results discussed with UniPath Referring Physician on 01/14/04.

TKW/ * Electronically Verified *
Traci Weyand
Decision Support Analyst
03/18/2005

Cytospin Morphology:

The cytospin and touch preparations display many small, normal appearing lymphocytes intermixed with a population of medium-sized cells with highly irregular nuclear contours and a high nuclear to cytoplasmic ratio with mature nuclear features. TKW/



Red= neoplastic T lymphocytes
Green= mature non-neoplastic T lymphocytes

Patient Name: UniPath, Sample Heme

Accession Number: FC88-000201

Birth Date: 1/1/1901 Age: 103

Date Obtained: 01/14/2004

Sex: Male

Date Received: 01/14/2004

Immunophenotypic Findings:

Immunophenotypic findings indicated a 35-40% population of small to medium-sized cells with the following immunophenotype: CD2(+),CD3(-),CD45(bright+),CD45RO(+),CD10(+),CD38(predominantly-),CD5(+),CD4(+),CD8(-),CD7(-),CD25(-),CD3(-).

Immunophenotypic analysis reveals an admixture of:

Small, Mature T Lymphocytes (CD4:CD8=0.88 : 1)	21.0	%
Small, Mature, Polytypic B Lymphocytes (Which Include 7% Germinal Center Cells 93% Primary Follicle/Mantle Zone Cells (Kappa:Lambda =1.3 : 1))	12.0	%
Plasma Cells	0	%
Monocytes	2.2	%
Granulocytes	4.3	%

The remaining events are attributable to debris.

TKW/

Leukocyte Marker Panel Performed:

Tissue Panel	Extra markers
10/19/20/38	10/2/3/5/6
2/RO/45/3	30/19/5/3
G2a/G1/G2a/G1	-/25/3/4
mK/mL/20/38	
pL/pK/5/19	
FMC-7/23/5/19	
7/4/8/3	

-/

This test was developed and performance characteristics determined by the UniPath, LLC. It has not been cleared or approved by the FDA. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research.